GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Debt-to-Revenue

Biogen (MEX:BIIB) Debt-to-Revenue : 0.76 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN4,149 Mil. Biogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was MXN111,138 Mil. Biogen's annualized Revenue for the quarter that ended in Mar. 2024 was MXN152,055 Mil. Biogen's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.76.


Biogen Debt-to-Revenue Historical Data

The historical data trend for Biogen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Debt-to-Revenue Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.58 0.69 0.65 0.75

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.67 0.76 0.77 0.76

Competitive Comparison of Biogen's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Biogen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biogen's Debt-to-Revenue falls into.



Biogen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biogen's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2546.137 + 122014.289) / 166951.914
=0.75

Biogen's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4149.064 + 111138.481) / 152054.888
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Biogen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biogen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024